BIOGEN INC. Payments to Acquire Other Investments
BIOGEN INC. (BIIB) reported Payments to Acquire Other Investments of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherInvestments · last filed 2020-02-06
- BIOGEN INC. payments to acquire other investments for the quarter ending 2019-12-31 was $0.00.
- BIOGEN INC. payments to acquire other investments for the quarter ending 2019-09-30 was $0.00.
- BIOGEN INC. payments to acquire other investments for the quarter ending 2018-12-31 was $0.00.
- BIOGEN INC. payments to acquire other investments for the quarter ending 2018-09-30 was $0.00.
- BIOGEN INC. payments to acquire other investments for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- BIOGEN INC. payments to acquire other investments for fiscal 2018 was $462.90M.
- BIOGEN INC. payments to acquire other investments for fiscal 2017 was $0.00.
- BIOGEN INC. payments to acquire other investments for fiscal 2016 was $0.00.
| Period end | Payments to Acquire Other Investments 3 month | Payments to Acquire Other Investments 6 month | Payments to Acquire Other Investments 6 month as first filed | Payments to Acquire Other Investments 9 month | Payments to Acquire Other Investments 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $0.00 derived: sum of 2 quarters · filed 2020-02-06 | $0.00 10-K · filed 2020-02-06 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $0.00 10-Q · filed 2019-10-22 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-07-24 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $0.00 derived: sum of 2 quarters · filed 2020-02-06 | $462.90M 10-K · filed 2020-02-06 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $462.90M 10-Q · filed 2019-10-22 | |||
| 2018-06-30 | $462.90M 10-Q · filed 2019-07-24 | $463.70M 10-Q · filed 2018-07-24 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $0.00 derived: sum of 2 quarters · filed 2020-02-06 | $0.00 10-K · filed 2020-02-06 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $0.00 10-Q · filed 2018-10-23 | |||
| 2017-06-30 | $0.00 10-Q · filed 2018-07-24 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-06 | ||||
| 2012-12-31 | $41.94M 10-K · filed 2013-02-05 | ||||
| 2011-12-31 | $9.81M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $12.37M derived: sum of 2 quarters · filed 2013-02-05 | $13.45M derived: sum of 3 quarters · filed 2013-02-05 | $16.32M 10-K · filed 2013-02-05 | |
| 2011-09-30 | $2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $3.64M derived: sum of 2 quarters · filed 2011-10-28 | $6.51M 10-Q · filed 2011-10-28 | $5.51M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2011-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $3.95M 10-Q · filed 2011-07-26 | $2.95M derived: sum of 3 quarters · filed 2013-02-05 | $6.11M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2011-03-31 | $2.88M 10-Q · filed 2011-04-21 | $1.87M derived: sum of 2 quarters · filed 2013-02-05 | $5.03M derived: sum of 3 quarters · filed 2013-02-05 | $5.66M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2010-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $2.15M derived: sum of 2 quarters · filed 2013-02-05 | $2.78M derived: sum of 3 quarters · filed 2013-02-05 | $4.49M 10-K · filed 2013-02-05 | |
| 2010-09-30 | $3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $3.79M derived: sum of 2 quarters · filed 2011-10-28 | $5.50M 10-Q · filed 2011-10-28 | $13.07M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-06-30 | $630.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $2.34M 10-Q · filed 2011-07-26 | $9.90M derived: sum of 3 quarters · filed 2012-02-03 | $11.22M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-03-31 | $1.71M 10-Q · filed 2011-04-21 | $9.28M derived: sum of 2 quarters · filed 2012-02-03 | $10.59M derived: sum of 3 quarters · filed 2012-02-03 | $13.84M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2009-12-31 | $7.57M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $8.88M derived: sum of 2 quarters · filed 2012-02-03 | $12.13M derived: sum of 3 quarters · filed 2012-02-03 | $44.09M 10-K · filed 2012-02-03 | |
| 2009-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $4.56M derived: sum of 2 quarters · filed 2010-10-26 | $36.52M 10-Q · filed 2010-10-26 | $39.63M derived: sum of 4 quarters · filed 2011-02-04 | |
| 2009-06-30 | $3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $35.20M 10-Q · filed 2010-07-20 | -$35.20M 10-Q · filed 2009-07-17 | $38.31M derived: sum of 3 quarters · filed 2011-02-04 | $67.19M derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-03-31 | $31.96M 10-Q · filed 2010-04-20 | $35.07M derived: sum of 2 quarters · filed 2011-02-04 | $63.94M derived: sum of 3 quarters · filed 2011-02-04 | ||
| 2008-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $31.98M derived: sum of 2 quarters · filed 2011-02-04 | $20.37M 10-K · filed 2011-02-04 | ||
| 2008-09-30 | $28.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | $17.26M 10-Q · filed 2009-10-21 | |||
| 2008-06-30 | -$11.61M 10-Q · filed 2009-07-17 | ||||
| 2007-12-31 | $23.67M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |